Authors
Latest:
Biosimilars in the US: Five Key Commercial ConsiderationsRohit Sood outlines five critical factors for companies entering this blossoming market.
Latest:
So What is Pharma’s Ideal Role in Social?Advertorial: Ashfield Commercial & Medical Services believes that Pharma can use social media to play an important role in educating the healthcare professional (HCP) and the patient
Latest:
Accelerated Change: Understanding the FDA’s Expedited PathwaysJamie Gault outlines the key differentiators between each of FDA's programs to facilitate and expedite drug development and review of new drugs.
Latest:
Patients, Physicians, and Payers… How Can Pharma Do it All?The word ‘centric’ by definition means one, as in focused on a single entity. Yet, in today’s life sciences industry, companies are customer-centric and patient-centric and physician-centric - combined. It's counterintuitive…if not overwhelming, writes Lisa Barbadora
Latest:
Personalized Medicine at a CrossroadsPersonalized medicine has reached a crossroads where fundamental change is not only appealing but essential, write Klarissa Hoday, Francesca Boggio, and Aleksander Ruzicic.
Latest:
Patients' Role in Healthcare Decisions Will Transform Industry’s Model of CareDavid Logue sees the industry adapting to address medical needs and deliver treatments to patients in ways that afford greater personal empowerment.
Latest:
Pharm Exec’s 14th Annual Press Audit: The Opioid Crisis Takes Center StageThe opioid crisis dominated the news in this year’s annual audit of press coverage of the pharmaceutical industry. George P. Sillup and Stephen J. Porth report.
Latest:
Five Indispensable Lessons from SXSWJanelle Starr was surprised to find this month's SXSW speakers talk about failure. But their failures are enlightening, and essential to their ultimate success.
Latest:
Data is Now the Key to MarketingNeil Gleghorn, looks at the upsurge of technology and metric-driven marketing operations in the strictly regulated pharmaceutical industries.
Latest:
The Goods and Services Tax: A Bane or a Boon for Indian Pharma?Dr. Anuj Gupta explains the potential implications of the GST- or the goods and services tax - on Indian pharma.
Latest:
FDA Steps Up Foreign InspectionsNew legislation and changes in policy at FDA are leading to better control of the API supply chain.
Latest:
Industry Optimism Outweighs Personal Job SecurityAmid the environment of a gradual economic recovery and continued consolidation of bio/pharmaceutical companies, scientists, technicians, and professionals involved in drug development expressed a mix of muted optimism and stagnant employment options.
Latest:
New Funding and Approval Pathways Prove PopularCompared to other manufacturing and technology industries, the bio/pharmaceutical industry has one of the longest product development timelines.
Latest:
In a Dynamic Healthcare Market, Only the Adaptive Survive“It is not the strongest of the species that survives, nor the most intelligent that survives. It is the one that is most responsive to change.” In today’s healthcare market, Darwin's words have never been more relevant, writes Brad Ansley.
Latest:
UnitedHealth’s Acquisition of PBM Catamaran Heralds Escalating Price War With DrugmakersLast week’s announcement by UnitedHealth Group of its planned acquisition of pharmacy benefits manager (PBM) Catamaran for $12.8 billion officially puts the pharmaceutical industry on notice that the “war” on drug prices is escalating, writes Michael Griffith.
Latest:
Fake Medications, Real SolutionsTactics pharma leaders can implement to stem the continued global threat of counterfeit drugs.
Latest:
HBA's Woman of the Year 2017For Bahija Jallal, chosen this year's Healthcare Businesswomen’s Association Woman of the Year, a passion for translational science has been the central guide in a career rise from cancer researcher to leading a big pharma biotech engine.
Latest:
Patent Strategy Implications in the Biosimilars SpaceColleen Tracy James and Neil DuChez ask, is biosimilar litigation the new frontier as predicted or an area pursued less vigorously as under the Hatch-Waxman Act because of cost and manufacturing obstacles?
Latest:
Accent on AccessibilityProgram provides effective, cost-efficient way to help patients overcome affordability barriers and obtain the critical medicines they need.
Latest:
Should You Outsource Analytics?Successful outsourcing can provide pharma companies with high-value, cost-effective analytics. But there are many challenges to overcome, write Ram Moorthy and Dharmendra Sahay.
Latest:
The Growing Importance of Real World DataStakeholders around the world can benefit from RWD as it can improve patient outcomes and speed at which products come to market.
Latest:
Pharma Transparency in Brazil: Latest DevelopmentsScott Lewin looks at Brazil's recently expanded transparency inititatives and how they affect pharma companies doing business in the region.
Latest:
Relationship-Centric Technology: Improving the Human Experience for Better EngagementRelationship-centric technology presents a sizable emerging opportunity for sponsors to improve the performance of clinical development, writes Tom O' Leary.
Latest:
Opposites Attract: Pairing R&D and Commercial TeamsMeike Wenzel and Clifford Hall examine a new concept for early commercialization planning to facilitate good cross-functional working practice.
Latest:
Multiethnic Marketing: The Billion-Dollar UpsideTapping into the fast-growing and lucrative “multicultural” segment requires new and more aggressive approaches to brand planning and consumer engagement.
